Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Safety Study of AR101 in Peanut-allergic Subjects from Prior AR101 Studies
2017-001334-26Phase 3Unknown
- Sponsor
- Aimmune Therapeutics, Inc.
- Start
- Sep 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peanut protein in peanut allergy, sponsored by Aimmune Therapeutics, Inc. Primary endpoint: Frequency of Adverse Events. Status: unknown.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2017-001334-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001334-26.